Cellectis S.A. (CLLS) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Journey Medical (DERM) has outperformed Cellectis S.A. (CLLS) over the past year, losing 55.8% versus a loss of 80.4%. Over five years, DERM leads with a -61.1% price change compared with -89.4% for CLLS. Journey Medical is the larger company by market cap ($93.2 million vs $92.8 million), about 1.0 times the size, while Cellectis S.A. is growing revenue faster (+75.8% vs +10.2%).
Journey Medical converts more of its revenue into profit, with a net margin of -18.5% versus -92.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | DERM |
|---|---|---|
| Share price | $0.9209 | $3.30 |
| Market cap | $92.76M | $93.16M |
| 1-day change | -7.89% | -7.04% |
| YTD return | -80.97% | -57.20% |
| 1-year return | -80.36% | -55.76% |
| 5-year return | -89.40% | -61.13% |
| EPS (TTM) | $-1.26 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.95M | $61.86M |
| Revenue growth (YoY) | +75.76% | +10.20% |
| Net income (latest FY) | $-67.59M | $-11.43M |
| Gross margin | 100.00% | 66.17% |
| Operating margin | -45.34% | -13.21% |
| Net margin | -92.66% | -18.48% |
| 52-week high | $5.45 | $9.56 |
| 52-week low | $0.881 | $3.21 |
| Distance from 52-week high | -83.10% | -65.46% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +497.24% | +286.36% |
| Average volume | 115.00K | 190.39K |
| Shares outstanding | 72.73M | 22.23M |
| Employees | 224 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed CLLS by 24.6 percentage points over the past year.
- Journey Medical is more profitable, keeping -18.5 cents of every revenue dollar as net income versus -92.7 cents for Cellectis S.A..
- Cellectis S.A. grew revenue faster in its latest fiscal year (+75.76% vs +10.20%).
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
CLLS vs DERM FAQ
Which is bigger, Cellectis S.A. or Journey Medical?
Journey Medical (DERM) is larger, with a market capitalization of $93.16M compared with $92.76M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or DERM?
DERM returned -55.76% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Journey Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.